Daewoong pharmaceutical Co.,Ltd

KSE 069620.KS

Daewoong pharmaceutical Co.,Ltd Free Cash Flow Yield on January 14, 2025: 1.06%

Daewoong pharmaceutical Co.,Ltd Free Cash Flow Yield is 1.06% on January 14, 2025, a -4.43% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Daewoong pharmaceutical Co.,Ltd 52-week high Free Cash Flow Yield is 1.29% on June 26, 2024, which is 21.95% above the current Free Cash Flow Yield.
Daewoong pharmaceutical Co.,Ltd 52-week low Free Cash Flow Yield is 0.78% on October 11, 2024, which is -26.21% below the current Free Cash Flow Yield.
Daewoong pharmaceutical Co.,Ltd average Free Cash Flow Yield for the last 52 weeks is 1.04%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

KSE: 069620.KS

Daewoong pharmaceutical Co.,Ltd

CEO	Mr. Chang-Jae Lee
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	12, Bongeunsa-ro 114-gil
Employees	1,710
Sector	Health Care
Industries Pharmaceuticals

Description

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years